Matches in Wikidata for { <http://www.wikidata.org/entity/Q90116101> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q90116101 description "artículu científicu espublizáu en marzu de 2020" @default.
- Q90116101 description "im März 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90116101 description "scientific article published on 03 March 2020" @default.
- Q90116101 description "wetenschappelijk artikel" @default.
- Q90116101 description "наукова стаття, опублікована 3 березня 2020" @default.
- Q90116101 name "Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy" @default.
- Q90116101 name "Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy" @default.
- Q90116101 type Item @default.
- Q90116101 label "Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy" @default.
- Q90116101 label "Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy" @default.
- Q90116101 prefLabel "Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy" @default.
- Q90116101 prefLabel "Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy" @default.
- Q90116101 P1433 Q90116101-2DB473AF-A2C0-49DD-8125-FD0EAF027892 @default.
- Q90116101 P1476 Q90116101-E71BC333-D5F8-4274-9545-D14C9CB32DE7 @default.
- Q90116101 P2093 Q90116101-03C1E21E-5E25-4310-A076-FCCD4B2A4F00 @default.
- Q90116101 P2093 Q90116101-08349A1B-638C-41A2-9990-C22B9DE92733 @default.
- Q90116101 P2093 Q90116101-08564FFB-F0C9-440E-B215-7F690EBEE926 @default.
- Q90116101 P2093 Q90116101-111BD3A3-7BD2-4465-9516-5A8007C31CB5 @default.
- Q90116101 P2093 Q90116101-268C2B41-3F8E-4997-AD59-BF7257ED2A3E @default.
- Q90116101 P2093 Q90116101-7B082D90-37DE-4BB3-B3DE-08F9BAD8E573 @default.
- Q90116101 P2093 Q90116101-87EFB172-1889-4874-95F1-891DC324832D @default.
- Q90116101 P2093 Q90116101-A7D582B6-4BBD-414D-BD09-2E69D005F02A @default.
- Q90116101 P31 Q90116101-B5CA2C03-91BE-45E1-9EE9-D6C654366B96 @default.
- Q90116101 P356 Q90116101-1D1A88E6-4978-45E8-AC97-499D3F60DA19 @default.
- Q90116101 P577 Q90116101-17CD4430-2D3D-4FD1-A662-D280F1EFD601 @default.
- Q90116101 P698 Q90116101-A3B7054F-A15E-4370-960A-8D3B1440E827 @default.
- Q90116101 P921 Q90116101-32490D42-37F7-45D6-B773-34D68EB9E392 @default.
- Q90116101 P356 J.EIMC.2020.01.017 @default.
- Q90116101 P698 32143893 @default.
- Q90116101 P1433 Q15766978 @default.
- Q90116101 P1476 "Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy" @default.
- Q90116101 P2093 "Ana Isabel López-Calleja" @default.
- Q90116101 P2093 "Antonio Oliver" @default.
- Q90116101 P2093 "Antonio Rezusta" @default.
- Q90116101 P2093 "Gabriel Cabot" @default.
- Q90116101 P2093 "Marta Fernández-Esgueva" @default.
- Q90116101 P2093 "Pablo A Fraile-Ribot" @default.
- Q90116101 P2093 "Rafael Huarte" @default.
- Q90116101 P2093 "Xavier Mulet" @default.
- Q90116101 P31 Q13442814 @default.
- Q90116101 P356 "10.1016/J.EIMC.2020.01.017" @default.
- Q90116101 P577 "2020-03-03T00:00:00Z" @default.
- Q90116101 P698 "32143893" @default.
- Q90116101 P921 Q31856 @default.